What Is New in the Treatment of Intraocular (Uveal) Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 October 2024 | Viewed by 1090
Special Issue Editors
Interests: plaque brachytherapy; uveal melanoma; eye physics; plaque simulator
Interests: eye cancer; retinoblastoma; ocular tumors; uveal melanoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Uveal, or intraocular, melanoma is the most common type of primary eye cancer in adults that begins in the uveal tract (iris, ciliary body, or choroid), and impacts most often older persons with fair skin and light-colored eyes more frequently. Although uveal melanoma is straightforward to diagnose via eye examinations, it has a high risk of migrating to other parts of the body, and an especially high risk of metastasizing in the liver. There are several courses of treatment depending on the size and history of the tumor. These may include surgery such as resection, enucleation, or exenteration, or radiation therapy through either external therapy (photon or proton beams) or internal therapy (plaque brachytherapy). Other treatments may include transpupillary thermotherapy, and new plaque-based and drug treatments.
Dr. Sheridan Meltsner
Prof. Dr. Miguel A. Materin
Dr. Oana Craciunescu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- plaque brachytherapy
- ocular tumors
- proton therapy
- transpupillary thermotherapy
- molecular prognostication
- gene expression
